Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science (RC2 Clinical Trials Optional)
Can you apply?
This grant is for eligible UM1 Clinical and Translational Science Awards (CTSA) Program Hubs seeking to develop and demonstrate specialized innovation capabilities. Applicants must be domestic U.S. entities or U.S. organizations. Non-domestic organizations and non-domestic components of U.S. organizations are not eligible. Foreign components within U.S. organizations are allowed.
The program supports development of hub capabilities, research platforms, and resources to address critical gaps in clinical and translational science. Funded programs should create foundations for future adoption and dissemination across additional CTSA Program Hubs.
Program description
The purpose of the High Impact Specialized Innovation Programs (SIPs) is to support the development and demonstration of unique hub capabilities, research platforms and/or resources to address in a timely manner critical gap areas and/or roadblocks in clinical and translational science at awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs (PAR-24-272). Successful programs supported through this funding opportunity are expected to lay a strong foundation for future adoption and/or dissemination of capabilities to additional CTSA Program Hubs.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- R&R SF424 (R&R) form
- Project Narrative
- Budget and Budget Justification
- Biographical Sketches (key personnel)
- Resource Sharing Plan
- Letters of Support/Institutional Commitment
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.350 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$139,753,636
-
$118,592,298
-
$118,098,707
-
$112,138,469
-
$102,422,256
-
$100,095,982
-
$99,978,264
-
$98,955,036
-
$98,090,822
-
$97,784,066
Top States by Funding
- CA 13 awards $652.0M
- NY 11 awards $496.8M
- MA 6 awards $321.4M
- NC 5 awards $313.7M
- OH 5 awards $162.0M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.350). How funding has trended year over year.
| 2024 | $595,597,945 | |
| 2025 | $626,227,752 |
FAQ
Who is eligible to apply for this grant?
UM1 Clinical and Translational Science Awards (CTSA) Program Hubs are the primary eligible applicants. U.S. organizations and domestic entities may apply. Non-domestic organizations cannot apply.
Can foreign organizations or non-U.S. entities apply?
No. Non-domestic organizations and non-domestic components of U.S. organizations are not eligible. Foreign components within U.S. organizations are permitted.
What types of innovations does this program support?
The program funds unique hub capabilities, research platforms, and resources. These should address critical gaps or roadblocks in clinical and translational science.
What is the expected outcome of funded projects?
Successful programs should create foundations for future adoption and dissemination of capabilities to additional CTSA Program Hubs.
When is the application deadline?
The deadline is fixed for September 28, 2026. Check the PAR-24-272 announcement for the current submission window.
💡 Tips for applicants
- Align your project directly with the UM1 CTSA Program's mission and hub capabilities. Reviewers prioritize alignment with existing hub infrastructure.
- Demonstrate how your innovation addresses a critical gap or roadblock in clinical and translational science. Clearly articulate the problem and your solution.
- Design your program with dissemination and adoption potential across other CTSA hubs. Show how your innovation can scale beyond your institution.
- Engage key stakeholders and collaborators from your hub in the proposal. Strong institutional commitment strengthens competitiveness.
- Use preliminary data or evidence to support feasibility. NIH high-impact grants favor proof-of-concept demonstrations over purely theoretical proposals.
⚠️ Common mistakes
Failing to demonstrate how the innovation will scale and be adopted by other CTSA hubs reduces competitiveness. Weak connection between proposed capabilities and critical gaps in clinical-translational science leads to unfavorable reviews. Insufficient preliminary data or feasibility evidence undermines impact assessments.
Similar grants
- OPEN FY26 Bureau of Land Management Rangeland Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Cultural and Paleontological Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Youth Conservation Corps – Bureau wide — Bureau of Land Management
- OPEN Infertility Training Center — Office of the Assistant Secretary for Health
- OPEN FY26 Bureau of Land Management Eastern Nevada Conservation, Recreation and Development – NEVADA BLM — Bureau of Land Management